Quantitative and qualitative studies of antibody–induced mesangial cell damage in the rat  by Yamamoto, Tadashi & Wilson, Curtis B.
Kidney International, Vol. 32 (1987), pp. 514—525
Quantitative and qualitative studies of antibody—induced
mesangial cell damage in the rat
TADASHI YAMAMOTO and CURTIS B. WILsoN
Department of Immunology, Research Institute of Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, California, USA
Quantitative and qualitative studies of antibody—induced mesangial cell
damage in the rat. Intravenous administration of heterologous anti-rat
thymocyte serum (ATS), which reacts with a Thy-i-like antigen present
on rat glomerular mesangial cells, caused lytic (1 hr to 2 days),
hypercellular (4 to 14 days), and sclerotic (2 to 3 months) mesangial
lesions in Lewis rats. The normal control of 48.6 7.9 (mean SD)
glomerular nuclei on histologic section decreased significantly (P <
0.001) to 39.8 6.1, 37.4 6.0, and 38.9 6.8 at one hour, four hours
and two days after ATS administration, respectively. Thereafter gb-
merular nuclei increased to 54.7 11.5 (P < 0.05) at four days, 62.5
9.6 (P < 0.001) at one week and 64,1 14.2 (P < 0.001) at two weeks,
and normalized (P > 0.05) to 49.4 8.9at one month and 50.6 9.0at
three months. By electron microscopy, gbomerular damage in the lytic
stage was restricted to mesangial cells and was manifested as hydropic
degeneration or lysis. Rabbit IgG and rat C3 were found in the
mesangium one hour after injection; they decreased at two days and
were negligible at four days. By paired label isotope study, 11.6 tg of
antibody bound per 7.6 x b0 glomeruli at one hour was needed to
induce mesangial cell degeneration. No or only minimal changes in
proteinuria and in serum creatinine were observed with the dosage used
in this rat strain. The glomerular uptake of aggregated human gam-
maglobulin, aggregated bovine serum albumin or preformed immune
complexes in ATS-treated rats exceeded that in controls by 13.9, 14.6,
and 4.1 times, respectively, at four hours after aggregate administra-
tion, but not at 24 hours, in quantitative studies of mesangial function.
The selective, antibody—induced glomerular cell—injury of this new
model contrasts with that of established models of glomerulonephritis in
which immune deposit formation and mediator activation cause rela-
tively—nonspecific glomerular inllammation.
The mesangial cell is thought to play a central role in immune
deposit forms of glomerular injury as well as in the normal
physiology of glomeruli [1]. In conditions such as IgA nephrop-
athy in humans, mesangial deposits are prominent and, rarely,
anti-mesangial antibody reactions have been suggested [2]. The
mesangium may help clear aggregates from the gbomerular
capillary lumen by the phagocytic function of its cells and by
transport through its channels [1, 3, 4]. Mesangial cells also
produce a number of products including enzymes, arachidonic
acid metabolites, and interleukin-i-like materials that could
influence the course of glomerular injury [5—8]. The mesangial
cell has angiotensin II receptors and can respond to this
stimulus [9], suggesting a role for the cell in glomerular hemo-
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dynamics. However, the mesangial cell has been hard to study
in vivo since there has been no easy way to selectively injure
the cell other than possibly with certain snake venoms [10, 11].
Recently, a Thy-i-like antigen was demonstrated in the rat
glomerulus by immunofluorescence microscopy using monoclo-
nal anti-Thy-i.! antibody or heterologous anti-rat thymocyte
antibody [12—14]. The Thy-i-like antigen was localized on the
surfaces of mesangial cells by immunoelectron microscopy [15,
16]. The induction of histological glomerular lesions by intra-
venous administration of heterologous anti-thymocyte serum
has been inconsistent. Bagchus et al found antibody binding to
the mesangium and the glomerular basement membrane in rats
that received heterologous anti-thymocyte antibodies; how-
ever, no light microscopic glomerular changes were observed
[17]. In contrast, Yamamoto et al found disappearance and
destruction of mesangial cells two days alter the administration
of anti-rat thymocyte serum [16, 18]. Mesangial lesions have
also been induced with intravenous administration of monocbo-
nal anti-thymocyte antibodies [19, 201. The mesangial cell injury
appears to occur independently of antiglomerular, basement
membrane antibody—mechanisms, which sometimes have been
associated with anti-lymphocyte sera [21].
To help clarify the concept of direct antibody-induced gb-
merular cell injury and to study the function of mesangial cells
in macromolecular clearance, we analyzed sequential changes
in ATS-induced glomerular lesions, quantitative gbomerular
binding of the antibody, and alterations of glomerular handling
of macromolecules. We found that in comparison to standard
immunologic models of glomerular injury only small amounts of
bound antibody were needed to induce the selective degenera-
tion and destruction of mesangial cells, subsequent mesangial
hypercellularity, and altered gbomerular uptake of macromolec-
ular aggregates and immune complexes.
Methods
Preparation and characterization of ATS
ATS was produced in New Zealand White rabbits by immu-
nization with I x 108 Lewis rat thymocytes in complete
Freund's adjuvant followed by 1 x 106 cells intravenously (i.v.)
two and four weeks later [14]. Sera obtained one week after the
last injection were heat inactivated (56°C for 30 mm) and
absorbed three times with packed Lewis—rat erythrocytes and
three times with crude Lewis rat, liver membrane fractions [22].
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The tissue reactivity of the ATS was studied by indirect
immunofluorescence using dilutions [1:25 to 1:10,000 in phos-
phate buffered saline (PBS), pH 7.2] on acetone—fixed cryostat
sections of normal rat kidney and thymus. To detect cross—re-
active antigens in the kidney, thymus, and other organs, ATS
was absorbed with rat thymocytes or lyophilized tissue powder
prepared from snap—frozen Lewis rat brain, kidney, liver, lung,
spleen and thymus; the residual reactivity was compared using
indirect immunofluorescence on Lewis rat kidney and thymus
sections.
To better define the glomerular antigenic determinants reac-
tive with the ATS, monocional antibodies (200 sg/ml) were
used to block the indirect immunofluorescence reactions to the
ATS. 0X7 reactive with rat Thy-i. and 0X2 reactive with rat
thymus glycoprotein (Accurate Chemicals and Scientific Co.,
Westbury, New York, USA) were used to pretreat tissue
sections for 30 minutes at room temperature. After washing
with PBS, the sections were reacted with dilutions of ATS and
stained with fluorescein isothiocyanate (FITC)-labeled goat
anti-rabbit IgG antibody (Cooper Biomedical Inc., Maivern,
Pennsylvania, USA) that had been absorbed to remove anti-
mouse IgG reactivity. The indirect immunofluorescence studies
were done as described above.
Induction of glomerular lesions with ATS
Female Lewis rats (6 to 7 weeks old) were used for i.v.
administration of ATS (0.05 to 2.0 ml/100 g body wt). Their
kidneys were then removed by unilateral nephrectomy and/or at
sacrifice at multiple time points between one hour and three
months later; three or more rats were used at each time point.
No histologic or functional changes were detected in the
kidneys from rats that received similar amounts of normal
rabbit serum.
The kidneys were examined by light, immunofluorescence
and electron microscopy. For light microscopy, the kidney
tissues were fixed in Bouin's solution and sections were stained
with periodic acid Schiff. To compare the glomerular cell
number semiquantitatively, nuclei were counted in over 30
glomeruli of 80 to 100 jsm diameter from each kidney. The
nuclei of polymorphonuclear leukocytes (PMNs) were counted
separately and fragmented debris of degenerating nuclei were
omitted. For immunofluorescence microscopy, renal tisues
were snap-frozen in liquid nitrogen and cryostat sections were
fixed in cold acetone for five minutes for staining with FITC-
labeled goat anti-rabbit IgG, rabbit anti-rat C3 and rabbit
anti-rat IgG (Cooper Biomedical Inc., Malvern, Pennsylvania,
USA). The intensity of glomerular staining was arbitrarily
graded from — to ++ +.
Smallpieces of kidneys were fixed with modified Karnovsky's
fixative at 4°C overnight and embedded in Epon. Ultrathin
sections were stained with uranyl acetate and lead citrate for
electron microscopy.
Urinary protein excretion was measured by the sulfosalicylic
acid method [23] in 24-hour urine samples collected daily in the
first two weeks after the ATS injection and weekly in the
following three months. Serum creatinine was determined by
the method of Heinegard and Tiderstrom [241.
Quantitation of ATS binding
To establish the kinetics of ATS binding to glomeruli, gam-
maglobulin fractions (precipitated by 50% saturated ammonium
sulfate) of ATS and normal rabbit serum (NRS) were labeled
with 125J and 'I, respectively [25], for paired label isotope
studies [21]. Mixtures containing 100 sg of each protein were
given i.v., and groups of four rats were sacrificed 15 minutes, 1,
6, 24, and 96 hours later. At sacrifice, the rats were perfused
with PBS through the right ventricle, and the brains, hearts,
thymuses, lungs, livers, spleens and kidneys were removed,
weighed, and the radioactivity determined. Protein—bound counts
in the plasma were determined by precipitation in a final
concentration of 10% trichloroacetic acid. Glomeruli were
prepared from the kidney cortex by passage sequentially through
#60- and #100-mesh screens. The radioactivity in the glomeruli
in suspension retained on a #200-mesh screen was determined
and their number estimated by counting 20 sl aliquots under a
light microscope. The glomeruli were then washed twice with
distilled water, frozen, lyophilized, and weighed. After the
radioactivity was counted, the other organs were also frozen in
liquid nitrogen, lyophilized, and weighed. The specific uptake
was calculated as follows: '251-specific organ count = 125J cpm
per organ-['311 cpm per organ x 125j cpm per ml plasma! 131j
cpm per ml plasma]. Specific organ uptake = specific organ
count/specific activity. Student's t-test for unpaired data was
used for statistical analysis.
The amount of glomerular—bound ATS necessary to induce
morphologically detectable glomerular injury was quantitated.
A 1/50 volume of '251-ATS and '311-NRS gammaglobulin (6.2 mg
rabbit IgG/ml each) was added to unlabeled ATS also contain-
ing 6.2 mg/mI of rabbit IgG, as estimated by radial immunodif-
fusion. Groups of two rats each received 0.05 to 5.0 ml of the
mixture per 100 g body weight. They were sacrificed one hour
after the injection, and the amount of rabbit IgG bound to their
isolated glomeruli was calculated as above.
Effects of ATS on the quantitative mesangial uptake of
macromolecular aggregates and immune complexes
Preparation of macromolecular aggregates. Heat—aggre-
gated human gammaglobulin (AHGG) was prepared as de-
scribed previously [26]. Human gammaglobulin (HGG, 20 mg/mi
in PBS) was mixed with '251-labeled HGG at a concentration of
20 pg/ml, heated to 63°C for 15 minutes, and cooled rapidly in
an ice bath. A 1/2.5 volume of 2.18 M sodium sulphate was
added and the mixture was stirred for 30 minutes at 4°C. The
resulting precipitate (3000 x g for 30 mm) was resuspended and
dialyzed against PBS. The dialyzed aggregated HGG was
centrifuged at 100,000 x g for 90 minutes, and the pellet was
resuspended in the cold PBS and centrifuged at 5,000 X g for 30
minutes to remove insoluble aggregates. The concentration of
protein was adjusted to 50 mg/mI of AHGG, including 50 g/m1
of '251-labeled AHGG and '311-labeled unaggregated HGG, for
use in quantitative, paired label experiments. The soluble
AHGG was characterized by sucrose density gradient (10% to
60% wt/vol) ultracentrifugation.
To prepare heat—aggregated bovine serum albumin (ABSA),
bovine serum albumin (BSA) was dissolved in 0.15 N NaCl, pH
7.0, at a concentration of 30 mg/mi containing 1251-labeled BSA
(30 g!ml). The solution was heated at 70°C for 20 minutes
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followed with shaking, and at 79°C for an additional five
minutes. The solution was rapidly cooled with tap water and 0.1
N HC1 solution was added to lower the pH to 5.2 to obtain an
insoluble precipitate. The mixture was centrifuged at 1000 X g
for 10 minutes and the precipitate was washed four times with
0.15 N NaCL, pH 5.2. The precipitate was then dissolved in
PBS, kept overnight at 4°C, and centrifuged at 2000 x g for 20
minutes to remove insoluble aggregates. The concentration of
ABSA was adjusted to contain 25 mg/ml including 25 pg/ml of
'251-labeled ABSA and '311-labeled unaggregated BSA each.
Soluble immune complexes of goat, anti-human IgG antibody
and HOG (20 mg/mi in saline) containing '251-HGG at a concen-
tration of 20 g/ml were prepared. The goat antiserum was
decomplemented (56°C for 30 mm), and the antibody content
was determined by quantitative precipitin analysis [27]; specific
antibody was present at a concentration of 11.5 mg/ml. Soluble
complexes were prepared by adding the equivalence amount of
HGG (20 mg/mI containing 20 pg/ml of '251-HGG) in saline to
the antiserum, mixing thoroughly and incubating the mixture at
37°C for one hour and 4°C overnight. The resulting precipitate
was washed with cold saline three times and resuspended in a
volume of HGG solution sufficient to give 20 times antigen
excess. The pH was lowered to 2.4 by dropwise addition of 1 N
HCL at 4°C. After complete dissolution of the precipitate, the
pH was readjusted to 7.0 by adding 1 N NaOH at 4°C. The
solution was centrifuged at 2000 x g for 20 minutes to discard
the insoluble aggregates. '311-goat gammaglobulin (GGG), pre-
pared from normal goat serum by 50% ammonium sulfate
precipitation, was added to the solution in a concentration
equivalent to the '251-HGG. The resulting solution contained 20
mg/ml of HGG and 20 zg/ml each of '251-HGG and '311-GGG.
The proportion of HGG formed immune complex was examined
by precipitation of '251-HGG in 3.5% polyethylene glycol, as
described previously [28].
Assessment of mesangial function. Mesangial damage was
induced by administration of 0.5 ml of ATS (or control NRS)
per 100 g body weight to 6-week old, female Lewis rats.
Twenty—four hours after the ATS or NRS injection, the rats
received 50 mg of AHGG containing 1251-AHGG and 1311-HGG
per 100 g body weight i.v. Four rats each receiving ATS or NRS
were sacrificed at one, four and 24 hours after administration of
the aggregate. Systemic clearance of the AHGG was measured
in rats destined for sacrifice 24 hours after the AHGG admin-
istration. The uptake of AHGG in organs or glomeruli was
measured by the paired label technique described above. The
kidneys were also examined by immunoffuorescence micros-
copy using FITC-goat anti-human IgG (Cooper Biomedical
Inc., Malvern, Pennsylvania, USA).
For ultrastructural localization of aggregate uptake by immu-
noelectron microscopy, small slices of renal cortex were fixed
with 2% paraformaldehyde, 0.2% glutaraldehyde, and 0.2%
picric acid in 0.1 M cacodylate buffer, pH 7,2, at 4°C overnight,
then postfixed with 0.05% osmium tetroxide in the same buffer
at room temperature for 15 minutes. The fixed pieces of tissue
were partially dehydrated through 30, 50, 70, 80% ethanol
series, embedded in L.R. White resin (London Resin Co.,
Hampshire, UK), and cured at 50°C for 48 hours. Thin sections
were mounted on uncoated #200-mesh nickel grids. Colloidal
gold granules ranging from 6 to 8 nm in diameter were produced
by the reduction of chloroauric acid with sodium borohydride
and complexed to goat, anti-rabbit IgG antibody (Dr. C.M.
Chang, Scripps Clinic and Research Foundation, La Jolla,
California, USA). The sections were first incubated with rabbit
anti-human IgO (40 sg/ml) in 0.05 M Tris-HC1 buffered saline,
pH 7.6, containing 0.3% BSA, followed by gold—goat anti-rabbit
IgG for one hour at room temperature. After immunolabeling,
the sections were further fixed in 1% osmium tetroxide for two
minutes and stained with aqueous uranyl acetate.
To further examine the effect of ATS on the glomerular
accumulation of AHGG, the dose of Al-lOG (50, 25, 10 or 2.5
mg) and the time intervals (simultaneously, 4 hr, 24 hr, 3 days
or 7 days) between ATS and AHGG administration were varied
in groups of three or more rats each. All animals were sacrificed
one hour after the AHGG injection for measurement of the
aggregate's uptake by glomeruli.
To study the effect of ATS on the glornerular localization of
ABSA, two groups of eight rats each were given either ATS or
NRS at a dose of 0.5 mIIlOO g body weight. Twenty—four hours
later, they were injected with 25 mg of ABSA containing 25
sg/ml of 1251-ABSA and '311-BSA per 100 g body weight. Four
rats from each group were sacrificed four and 24 hours after the
ABSA administration.
To compare the glomerular uptake of AHOG and ABSA with
that of preformed immune complexes, two groups of 10 rats
received either ATS (0.5 mI/l00 g body weight) or NRS i.v. 24
hours before administration of the immune complex preparation
(x 20 antigen excess) containing 40 mg of HGG per each 100 g
body weight. Five rats from the ATS- and NRS-treated groups
were sacrificed at four and 24 hours. The specific uptake was
expressed as sg of AHGG, ABSA, and HOG (in preformed
immune complexes) per 5 x i04 glomeruli or per mg of dry
organ weight.
Results
Characterization of ATS
In vitro, the ATS bound conspicuously to the mesangial area
of the glomeruli in kidney sections from normal rats (indirect
immunofluorescence) as well as to margins of thymocytes on
thymus sections; the end—point titer was 1:3000 on both organs.
No reactivity characteristic of anti-glomerular, basement mem-
brane antibodies was seen [21]. After absorption of undiluted
ATS with 1/4 volume of rat thymocytes, binding to the kidney
and thymus was abolished even at dilutions as low as 1:10.
The results of ATS absorption by powdered tissue are shown
in Table 1. Small amounts of brain or thymus powder eliminated
the reactivity of ATS to both the renal glomerulus and thymus.
Larger amounts of spleen or kidney powder absorbed the
binding of ATS to both organs. Heart or lung powder absorbed
minimally, and liver powder did not absorb this activity. The
indirect immunofluorescence reaction of a 1:100 dilution of the
ATS was abolished by pretreatment of the target sections of
kidney and thymus with the monoclonal antibody 0X7 (reactive
with rat Thy-i.!), but not 0X2, which reacts with an unrelated
antigen shared by the brain, thymus, and glomeruli. 0X7
reacted with glomeruli in an immunofluorescence pattern simi-
lar to that of the ATS. Blocking with the amount of 0X7 used
was minimal when the ATS was diluted only 1:10.
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Table 1. Amounts of various organ powders needed to abso
reactivity with glomeruli and thymus
rb ATS
ATS dilution 1:25 ATS dilution 1:100
.Tissue
powder
IF target IF target
Glomerulus Thymus Glomerulus Thymus
Brain
Heart
Kidney
Liver
Lung
Spleen
Thymus
5 25 I
> 50 > 50 50
> 50 > 50 50
> 50 > 50 > 50
>50 >50 50
50 > 50 25
1 25 1
I
> 50
25
> 50
50
10
5
The ATS (200 1) was absorbed with varying amounts (1, 5, 10, 25, or
50 mg) of lyophilized organ powders. The reactivity of absorbed ATS
was examined by indirect immunofluorescence on Lewis rat kidney and
thymus sections. The values represent the amount of organ powders in
mg needed to absorb the reactivity.
ATS-induced glomerular lesions
In vivo, only trace amounts of rabbit IgG were found in the
glomeruli of rats given 0.05 or 0.2 mi/lOU g body weight of ATS
two days earlier. These rats had no histological abnormalities
by light microscopy. 0.5 ml ATS/100 g produced a mild to
moderate deposition of rabbit IgG in the mesangium, enlarge-
ment of glomerular tufts, and decreased glomerular cellularity
at day 2. The mesangial deposits at day 2 were more intense
when larger amounts of ATS (2.0 ml/l0O g) were given. After
seven days, rats receiving 0.5 mI/lOU g had no immunofluores-
cent deposits; however, ballooned glomerular tufts and focal
mesangial hypercellularity were conspicuous.
In the sequential histological studies of the ATS-induced
glomerular lesions, a small decrease in nuclear counts with
karyorrhexis and pyknosis of nuclei and a slight infiltration of
PMNs were observed within one hour after ATS administration
(0.5 ml/l00 g body weight) (Fig. 1A, Table 2). Electron micros-
copy showed degenerated mesangial cells, leaving epithelial
cells or endothelial cells intact, and the mesangium was occa-
sionally infiltrated with PMNs (Fig. 2A, B). Rabbit IgG and rat
C3 were found in the mesangium by immunofluorescence
microscopy at one hour (Fig. 3A, B). The glomerular lesions
examined at four hours resembled those viewed at one hour. By
two days, the low—grade PMN infiltration was gone, as were
most mesangial cells. Focal areas of the mesangia ballooned
and filled with plasma (Fig. 2C), a lesion regarded as mesangi-
olysis. A small degree of focal mesangial hypercellularity was
evident.
By day 4, the glomeruli were enlarged with focal to diffuse
mesangial hypercellularity (Fig. lB. C), increasing the glomer-
ular nuclear counts (Table 2). Occasional PMNs were present,
particularly in the areas of mesangial ballooning, that were filled
with proteinaceous deposits. Staining for rabbit IgG and rat C3
was weak or negligible (Table 2). By electron microscopy, there
were two morphologically different cells in the expanded me-
sangium; the major cell type was characterized by cells with a
large nucleus, single large nucleolus, relatively scant cytoplasm
with a smooth cell surface, and scant organelles other than
rough endoplasmic reticulum (Fig. 4A). The other cell type had
Table 2. Glomerular cell counts and immunofluorescence findings
Light Immunofluores-
microscopy cence
Time after ATS No. of No. of Rabbit
injectiona N Nuclei/Gl PMN/Gl IgG Rat C3
1 hr 3 39.8 6.1" 2.4 04b
4 hr 3 37.4 6.0" 2.8 02" +
2 days 3 38.9 6.8" 0.3 0.1 + +
4 days 3 54.7 ll.5c 0.7 0.3
I week 3 62.5 9.6" 0.1 0.1 — —
2 weeks 3 64.1 14.2" 0.2 0.1 — —
I month 3 49.4 8.9 0.1 0.0 — —
3 months 3 50.6 9.0 0.2 0.1 — —
Normal rats 4 48.6 7.9 0.2 0.1 — —
The numbers of nuclei and PMNs were counted individually in over
30 glomeruli (Gl) ranging from 80 to 100 sm in diameter on 2 im thick
sections. The values are expressed as mean 1 SD. Student's t-test was
used for statistical analysis in comparison to normal control rats.
a 0.5 mlIlOO g body weight, significantb < 0.001
P < 0.05
pseudopods on the surface and plentiful cell organelles includ-
ing phagosomes (Fig. 4B). Both types of cells occupied the
mesangiolytic areas and clustered in ballooned regions.
The proliferative lesion persisted at two weeks (Fig. lD) but
had largely subsided by one month and more so at three
months, leaving a focal increase in the mesangial matrix and
mild sclerotic changes (Fig. 1E). Minimal increases in urinary
protein excretion (less than 20 mg/day) occurred during the first
24 hours after ATS injection in some rats, but thereafter no
significant proteinuria (more than 5 mg/day) was detected.
Creatinine increased slightly but uniformly from a mean of 0.53
mg/dl (baseline) to 0.72 mg/dl at four days after ATS injection (P
<0.05). Larger amounts of ATS (0.75 ml or 1.00 mI/100 g body
wt) did not increase urinary protein excretion (>20 mg/24 hr) or
serum creatinine (>1.0 mgldl) during the first 14 days after
ATS.
Quantitation of glomerular binding of A TS
In paired, label radioisotope studies, ATS administered at a
dose of 100 pg/100 g body weight bound to glomeruli after only
15 minutes and the binding was maximum at one hour. The
amounts of ATS bound in glomeruli, and livers appear in Table
3. No or minimal '251-ATS was found in the lungs, brains,
hearts, spleens, or thymuses from rats given the ATS 15
minutes, 1, 6, 24 and 96 hours before sacrifice.
The amount of ATS bound to glomeruli at one hour increased
linearly with increased dose, as shown in Table 4. The admin-
istration of the lesion inducing amount of 0.5 ml ATS/100 g body
weight resulted in about 7.6 g of rabbit IgG binding to 5 X 1O
glomeruli. If a total of 3.8 x io glomeruli per kidney is assumed
[29], then the minimum amount of ATS necessary to produce
the mesangial lesions can be calculated as 11.6 ig/2 kidneys.
Quantitation of mesangial function
The uptake of AHGG in various organs was quantitated in
ATS- or NRS-treated rats. By sucrose density gradient analy-
sis, the AHGG preparation was slightly larger than human 1gM
and contained about 10% unaggregated HGG. The uptake of
Fig. 1. A. Ar 1 hr after ATS a decrease in the number of
glomerular cells nas evident. Degenerating mesangial
cell nuclei (arrows) and a PMN (hatched an-ow) were
present. The higher power inserts show a PMN on the
left and a degenerating mesangial cell on the right.
B. Marked expansion of the mesangial regions with
mononuclear cells was found 4 days after ATS
injection. C. Occasionally ballooning of the glomerular
tuft, with proteinaceous debris (arrow) and scant
cellularity, was present 4 days after ATS administration.
D. Segmental mesangial hypercellularity (arrows) and
increased mesangial matrix were present 2 weeks after
giving ATS. E. A segmental increase in mesangial
matrix (arrows) was found 3 months after ATS
injection. (Periodic acid Schiff; original magnification
A—E )< 312. insert A x 1250).
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Fig. 2. A. D4ffuse degeneration of mesangial cells (arrows) was observed 1 hr afterATS injection. PMNs were occasionally present in the mesangial
areas. B. Mesangial cell destruction (arrow), preserving continuous endothelial cell lining (hatched arrows) and foot processes of epithelial cells,
was noted 1 hr after ATS administration. C. Mesangial cells had disappeared in areas with residual endothelium (arrows) intact 2 days after ATS
injection. (Original magnification: A, x 1800; B, x 9600; C, x 7200).
Fig. 3. Mesangial deposits (arrows) of rabbit IgG (A) and rat C3 (B)
were found in glomeruli 1 hr after A TS injection. (Original magnification
x 400).
AHGG by renal glomeruli in ATS-treated rats increased re-
markably at one and four hours in comparison to that in
NRS-treated control rats; however, a rapid decrease occurred
thereafter, and there was virtually no difference between the
ATS- and NRS-treated rats at 24 hours. In both groups uptake
of AHGG was similar in livers, lungs, and spleens (Table 5) as
well as in hearts and thymuses (data not shown). Large amounts
of AHGG accumulated transiently in the liver (Table 5). No
significant difference occurred in the clearance of AHGG from
the circulations of these two groups (Fig. 5).
In comparison to control animals (Fig. 6A), the immuno-
fluorescent intensity and the distribution of AHGG in the
mesangia of ATS-treated animals (Fig. 6B) were greater at one
and four hours after the AHGG administration. However, by 24
hours the AHGG deposition was minimal in both groups, which
correlated with the quantitative data.
Electron micrographs showed only small electron dense
deposits in the mesangial areas of control kidneys obtained one
or four hours after the AHGG injection in contrast to extensive
deposits in the mesangia after ATS administration. The mesan-
gial cells themselves frequently exhibited hydropic degenera-
tion in the ATS-treated rats. The electron dense deposits in the
mesangium were confirmed as human IgG by immunoelectron
microscopy (Fig. 6C). The gold—labeled anti-rabbit, IgG anti-
body used in the immunoelectron microscopy studies did not
detect the rabbit IgG of the ATS when administered alone. This
may have been due to the lessor amounts of IgG present in the
mesangium and the relative insensitivity of the direct rather
than indirect techniques used.
The effect of ATS on the glomerular deposition of varying
doses of AHGG was examined (Table 6). A significant increase
(P <0.05) in the glomerular uptake in ATS-treated rats was
found even with 2.5 mg AHGG per 100 g body weight.
The time interval between ATS and AHGG administration as
a factor in deposition was also studied by the paired label
radioisotope technique. Glomerular uptake of AHGG increased
signficantly in all rats given ATS 7, 3, and 1 day or 4 hours
before the AHGG administration, with the maximum value at
the four hour interval (Table 7). A minimal increase in the
glomerular uptake of AHGG was found in rats that were given
ATS and AHGG simultaneously.
An increase in the accumulation of ABSA was found in the
kidney and glomeruli from the ATS-treated rats given ABSA
a
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Fig. 4. A. Two types of mononuclear cells were found in the mesangial regions 4 days after ATS administration. One type had a large nucleus and
large nucleolous (arrows). The endothelium remained well preserved (hatched arrow), maintaining capillary integrity. B. The other cell type had
pseudopods (double hatched arrow) and many cell organellas, and was presumed to be a monocyte/macrophage. The first cell type (arrow) is shown
for contrast, The endothelium (hatched arrow) was intact. (Original magnification: A, X 3000; B, x4800).
Table 3. Specific binding of '251-ATS
Time after ATS administration uptake
Tissue 15 mm
as g/g dry weight
1 hr 6 hrs 24 hrs 96 hrs
Glomeruli 7.8 0.9 11.6 0.9 8.0 0.5 3.4 0.5 2.5 0.7
Liver 0.0 0.0 0.1 0.0 0.4 0.1 0.3 0.0 0.1 0.0
Rats received 100 sg each of '231-ATS and uhINRS gammaglobulin
fractions intravenously and were sacrificed at the time intervals shown
in the Table. The specific uptake in the organs was calculated as g
protein per gram weight of dried organ. The values are mean 1 SD (N
= 4 per time point). No or minimal specific uptake was found in lungs,
brains, hearts, spleens, or thymuses.
four or 24 hours before sacrifice. In this experiment, the
difference in glomerular uptake between control and ATS-
treated rats remained significant even after 24 hours, whereas
the other organs took up equivalent amounts in both groups
(Table 8). The clearance of ABSA from the circulation was also
the same in both groups.
The proportion of radiolabeled HGG precipitated by addition
of polyethylene glycol to the preformed immune complex
preparation was 88.3%, whereas less than 5% of control mono-
Table 4. Binding of rabbit IgG to glomeruli one hour after
intravenous administration of large amounts of ATS
Uptake in 5 x l0
Body weight
glomeruli
Mesangial cellRat 1 Rat 2
ml ATS/100 g jg sg degeneration
0.05 2.8 3.9 no
0.2 4.0 4.9 no
0.5 7.5 7.8 yes
2.0 11.6 15.5 yes
5,0 19.4 24.3 yes
The values are sg rabbit IgG bound to 5 x l0 glomeruli prepared
from the two individual rats used for each ATS dose.
meric HGG was precipitated by the procedure. More of the
preformed immune complexes accumulated in glomeruli from
ATS-treated rats than from controls when examined four hours
after the injection, and the residual amount of these complexes
in the glomeruli at 24 hours was less in treated than in control
rats (Table 8), There were no significant differences in other
organs between control and ATS-treated rats. There was no
significant difference in the clearance of the preformed immune
complexes from the circulation between two groups.
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pg/mg Dry weight, pg/S x JO glomeruli
lhr 4hr 24hr
Glomeruli
ATS 96.5 l9.1
(453.1 28.3a)
24.4 3.1
(126.7 190b)
1.1 0.2
(6.3 1.1)
control 4.1 1.4
(11.2 3.0)
2.2 0,5
(9.1 1.1)
0.9 0.4
(5.0 1.0)
Liver
ATS 12.1 3.7 6.8 1.8 0.2 0.1
control 13.4 4.4 6.1 0.3 0.2 0.1
Lungs
ATS 2.1 0.4 0.7 0.1 0.1 0.0
control 2.3 0.8 0.9 0.2 0.1 0.0
Spleen
ATS 12.8 1.3 2.4 0.3 0.3 0.1
control 12.2 0.7 2.7 0.5 0.3 0.0
The rats pretreated with ATS or control NRS 24 hr earlier were
injected with '251-AHGG (50 mg/100 g body wt) and sacrificed at the
intervals shown. The uptake of AHGG (pg) per mg dry weight of organ
is expressed as mean I 5D. The uptake per 5 x l0 glomeruli before
drying is given in parentheses.
Statistically significant (P < 0.001) between control (N = 4) and
ATS-treated rats (N = 4)
b P < 0.05
Discussion
This model constitutes a prototype of a new class of nephri-
togenic immunologic reaction in which antigens believed to
exist naturally, or perhaps trapped, on the surface of glomerular
(or tubular) cells can serve as targets for nephritogenic immune
attack. The immunopathogenesis of glomerular injury, until
recently, has been considered to be secondary to immune
deposit formation by one of several mechanisms [30], with
subsequent immune mediator—induced inflammation, leading to
nonspecific damage to surrounding structures. The model de-
scribed herein results in specific and selective injury in an
anatomic structure containing multiple cell types. Other poten-
tial glomerular cell surface antigens being considered candi-
dates in this type of reaction would be angiotensin converting
enzymes on the surface of endothelial cells [31, 32], the
epithelial cell, foot process antigen of spontaneous glomerulo-
nephritis in rabbits [33], and the Heymann's nephritis gp330
reactant identified on epithelial cells, as well as on the brush
border area of the renal proximal, tubule epithelial cell [34—36].
The latter antigen system has been used also as a target for
damage to proximal tubular cells [37, 38].
In the ATS-induced glomerular lesion, the relevant target is
the mesangial cell and the selective damage of mesangial cells
was apparent in the electron micrographs. Specific binding of
intravenously administered ATS to mesangial cell surface has
been found [16]. The early decrease in mean glomerular cell
number from 48.6 to 37.4 to 39.8 per glomerulus within two
days could be interpreted to mean that 72.4 to 92.2% of the
mesangial cells, estimated to comprise about 25% of glomerular
cells [39], were damaged by the ATS treatment.
The antigen recognized with ATS is probably Thy-i on the
mesangial cells because the reactivity of ATS with glomeruli
was completely absorbed with thymocyte or brain powder and
largely inhibited by monoclonal anti-Thy-l.l antibody, but not
by a monoclonal antibody reactive with another antigen shared
by the brain and thymus. In addition, a Thy-l-like antigen was
previously localized in glomeruli by immunofluorescence [12—
14] and on the surface of mesangial cells by immunoelectron
microscopy [15, 16]. The Thy-i antigen is one of the lympho-
cyte differentiation antigens [40], and in the rat is found on
thymocytes and a portion of nucleated, bone marrow cells [41].
Most peripheral T lymphocytes are Thy- 1 negative in the rat, in
contrast to their positive state in mice [42]. The lack of antigen
on circulating cells may facilitate its ability to reach the mesan-
gial area.
Mesangial cell death resulted from the binding of about 11.6
g antibody per 7.6 x l0 glomeruli (the assumed glomerular
content of two rat kidneys [29] one hour after ATS administra-
tion. This led to the initial lytic and subsequent prolifera-
tive/infiltrative lesions in the mesangium. In quantitative terms,
the amount of glomerular—bound antibody required to cause the
lesion was less than that usually necessary to induce glomerular
injury in immune deposit forms of experimental rat nephritis.
For example, about 150 g of antibodies/2 kidneys are required
to produce heterologous phase anti-glomerular, basement mem-
brane nephritis [43], and a similar amount of anti-Con A
antibody is needed in the Con A planted antigen model of
glomerular injury [44]. In contrast to these models in which
immune deposits and mediator activation damage surrounding
glomerular tissues, the anti-Thy-i antibody reacts with the
surfaces of mesangial cells, presumably damaging them di-
rectly. Accordingly, it is not surprising that the direct effect
described here should require less antibody to produce its
focused injury. Preliminary studies suggest that the acute
antibody—induced, mesangial cell injury depends on comple-
ment and can be suppressed by decomplementation with cobra
venom factor, but not leukocyte depletion using irradiation or
anti-PMN serum [18, 45, 46]. In addition, late components of
complement (CS, C6, C7, C9, C5b-9 complex) were defined by
indirect immunofluorescence in the mesangium of the kidneys
which were obtained one hour after the ATS injection [46]. The
localization of these components was closely associated with
Table 5. Time course of AHGG uptake in glomeruli and organs
E
E
C:,
0
0)
E
Time, mm
Fig. 5. Clearance of '251-AHGG from the circulation in control (open
circles) and ATS-treated rats (closed circles). The bars depict 1
standard deviation,
5 15 30 60 240 480 1440
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Fig. 6. A. Small, focal deposits of human IgG were found in the mesangium of a control rat given AHGG 1 hour earlier. B. In contrast, massive,
diffuse deposits of human IgG were present in the mesangium of a rat given AHGG that had received ATS 4 hr earlier. C. The colloidal gold
technique was used to identify AHGG (human gammaglobulin) in the glomeruli at the electron microscopic level. The black colloidal gold particles
(arrows) are packed in the mesangial areas corresponding with electron dense deposits. Abbreviations are: EP, epithelial cell; US, urinary space;
EN, endothelium; CL, capillary lumen; GBM, glomerular basement membrane. (Original magnification A, B x 400; C x 14,000).
Table 6. Dose response of AHGG uptake in glomeruli and liver
'25IAHGG
mg/100 g body wt
Glomeruli Liver
/.Lg/mg Dry
weight
,g/mggf5 x IO Dry weight
50mg
ATS
control
25
ATS
control
10
ATS
control
2.5
ATS
control
453.1 28.3a 96.5 l9.l
11.2 3.0 4.1 1.4
185.0 42,5a 35.0 59
4.6 2.5 0.9 0.4
14.1 1.6" 3.3 04b
6.0 3.7 1.3 0.7
1.5 04b 0.3 01b
0.7 0.2 0.1 0.0
12.1 37
13.4 4.4
12.7 0.9
12.3 1.9
8.2 1.5
9.2 1.3
2.3 0.6
2.4 1.1
All groups (four rats each) pretreated with ATS or control NRS 24
hours earlier were sacrificed one hour after the administration of 1251
AHGG for measurement of the uptake by paired label method. The
uptake of AHGG is expressed both in microgram per 5 x io glomeruli
and per mg dry weight of glomeruli or liver. Data are mean 1 SD.
a p < 0.001
bP < 0.05
that of rabbit IgG and rat C3. Similar glomerular lesions to the
ATS-induced lesions were demonstrated in rats by intravenous
administration of complement—fixing, monoclonal anti-thymo-
cyte antibody but not by non-complement—fixing antibody [19].
These results suggest that the membrane attack complex [471,
formed on the mesangial cell membrane, plays a role in the cell
injury and the following proliferative response.
Table 7. Time of ATS administration versus uptake of AHGG
ATS
Glomeruli .Liver
.Lg/mg
Dry weightg/5 X JO"
pg/mg
Dry weight
—7 days 74.5 16.4a 9.7 2.4a 8.6 0.3
—3 days 177.0 40.9a 25.6 43 7.8 0.6
—1 day 182.9 50.8a 24.7 6.3a 9.6 0.3
—4 hours 643.4 83.7a 78.2 14.5a 10.1 0.9
0 40.8 28.8 5.5 3.7 9.4 1.6
control 13.5 3.2 2.1 0.3 9.7 0.3
All groups (three rats each) given ATS at the times specified or left
untreated (control) were sacrificed one hour after the '251-AFIGG
injection (50 mg/100 g body wt). Both the uptake of AHGG (gig) per 5 x
l0 glomeruli and per mg dry weight of glomeruli, as well as liver uptake,
are represented as mean 1 SD.
a P < 0.001
The role of mesangial cells in the accumulation of aggregates
within glomeruli is not completely understood, and the degree
of phagocytic activity of these cells is not quantified [4, 481. To
assess the effect of selective mesangial cell damage on the
mesangium's uptake of macromolecular substances, several
large aggregates were prepared and given to rats that had
received ATS i.v. Immunofluorescence studies and quantita-
tive, paired labeled experiments both showed a remarkable
increase in the glomerular uptake of these aggregates in ATS-
treated cells. Immunoelectron microscopic studies confirmed
that the massive deposition of aggregates was exclusively in the
-
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Table 8. Uptake of ABSA and preformed immune complexes four or
24 hours after administration
Uptake of ABSA pg/mg Dry Uptake of immune complex-
weight es tg/mg Dry weight
4hr 24hr 4hr 24hr
Glomeruli
ATS 81.4 59 17.7 69b 36.4 51b 0.6 04b
(333.2 45.2k) (78.0 290b)(1880 220b) (4.6 2.1)
Control 7.3 2.7 0.8 0.3 11.3 2.1 2.7 1.6
(22.9 6.7) (3.5 1.0) (45.9 13.7) (10.1 5.0)
Liver
ATS 0.4 0.0 0.0 0.0 11.7 1.4 1.4 0.7
Control 0.4 0.0 0.0 0.0 13.7 1.8 1.4 0.5
Spleen
ATS 3.5 0.5 1.3 0.2 2.8 0.6 1.5 0.1
Control 3.0 0.6 1.1 0.2 3.0 0.5 1.6 0.2
The rats pretreated with ATS or NRS (control) 24 hours earlier
received '251-ABSA (25 mg/100 g body wt) or preformed immune
complexes (40 mg '251-HGG/100 g body wt). The data (mean I SD, N
= 4 or 5) are presented as sg uptake of ABSA or HGG in preformed
immune complexes per mg dry weight of organ. The uptake per 5 x iO
glomeruli before drying is given in parentheses.
P < 0.001
b p < 0.05
mesangial area. The cause of the increased uptake in the
glomerular mesangium was intraglomerular factors, since there
were no differences in the clearance of aggregates from the
circulation or uptake in the reticuloendothelial system, such as
liver or spleen, between control and ATS-treated rats. The
increased mesangial accumulation of macromolecular aggregate
must be the consequence of an alteration in the balance
between ingress (uptake) and egress (disposal). The striking
increase in the one hour mesangial accumulation of AHGG in
rats treated four hours to seven days earlier with ATS must
reflect either or both facilitated transportation of AHGG from
the circulation to the mesangium (ingress) and a reduced egress
by transport via the mesangial channels or back to the glomer-
ular capillary as well as any contribution by mesangial cell
processing. The current study cannot differentiate between
those possibilities. However, it does appear that mesangial
uptake of macromolecules increases remarkably when the
mesangial cell is injured or when inflammatory reaction, includ-
ing complement activation, focuses on the mesangium.
The rapid removal of the large amount of AHGG (and other
macromolecular markers) initially trapped suggests that mesan-
gial cell processing, which was no longer possible during the
lytic phase of injury, can occur without active participation of
the mesangial cell. Actually, egress may have been facilitated
by the disruption of the normal mesangial architecture, allowing
more rapid movement of the macromolecules into the vascular
stalk or elsewhere. Another possibility is that the immunoglob-
ulin containing aggregates, AHGG, and immune complexes
were acted on by the few PMNs that accumulated in the
glomeruli or by monocytes in the mesangial areas [49, 50], as
well as attracted there, as reported, after injection of immune
complexes into mice [48]. In support of this idea, more ABSA
persisted in the mesangium 24 hours after its introduction when
compared with AHGG and preformed immune complexes. This
may be attributed to less immunoreactivity of ABSA than
AHGG or immune complexes in terms of Fc or possibly
complement receptor interactions with monocytes or PMNs.
However, the number of infiltrating cells in a glomerulus is
small during the early hours of the ATS-induced lesion; there-
fore, their contribution to the clearance of mesangial deposits
may not be marked.
The origin of the mesangial—proliferative lesions that fol-
lowed two to four days after ATS administration remains to be
defined. The electron microscopic studies suggest that the cells
are composed of both mesangial cells and infiltrating leuko-
cytes. In preliminary studies, leukocyte depletion using irradi-
ation only diminished somewhat but did not prevent the hyper-
cellular lesion [18], suggesting that the majority of cells were
actually mesangial in nature. The lesion resolved with residual
increase in mesangial matrix and focal sclerosis, a response also
presumed to reflect the mesangial cell response to the initial
destructive phase of injury.
Mesangial damage consisting of focal ballooning and hyper-
cellularity has been observed in rats and rabbits given Habu
(Trimeresurus flavoviridis) venom i.v. [10, 11]. The Habu
venom lesion is much less extensive in rats than the ATS-
induced lesion, and the mesangial cells tend to be preserved
intact or unaffected. The Habu venom—induced lesion is con-
sidered to be generated, at least in part, by enzymatic activity of
the venom on mesangial matrix. Venom-induced platelet aggre-
gates may also contribute to endothelial damage, and coagula-
tion may also play a role [11].
Of interest, the striking glomerular lesion associated with the
ATS-induced mesangial cell injury, lysis, and proliferation/in-
filtration caused only minimal changes in excretion of protein in
the urine and serum creatinine elevation. The same antibody
given to Munich—Wistar rats did cause greater proteinuria (data
not shown), suggesting that strains may differ in the severity of
pathophysiologic manifestations. Since the glomerular capillary
wall serves as the major filtration barrier, it is perhaps not
surprising that selective mesangial injury would not be associ-
ated with marked changes in glomerular solute or macromolec-
ular clearances. Recently, proteinuria was produced in Wistar
rats using a monoclonal anti-Thy- 1.1 antibody which reacted
along the glomerular basement membrane as well as in the
mesangium [19, 20].
The identification of an antibody and presumably comple-
ment—associated mechanism of selective mesangial cell injury
adds an important new dimension to the current concepts of
immunopathologic mechanisms of renal injury. Now direct and
selective mechanisms of renal cell injury must be considered
alongside the well established but less selective forms of
immune glomerular insult generated by various modes of anti-
body accumulation in the glomerulus, followed by humoral and
cellular mediator activation with indiscriminate injury to adja-
cent structures. The selective mesangial injury was associated
with marked changes in glomerular handling of macromolecular
aggregates; however, in spite of severe histologic changes, little
effect was seen on glomerular clearance of small or large
molecules defined by serum creatinine and urinary protein
measurements. This selective effect on function of various
glomerular structures is not usually achieved with less specific
forms of immune insult. The human counterparts of the new
immunologic mechanism remain to be defined. The report of
anti-mesangial antibody activity in immunoglobulin eluted from
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the kidneys of a patient with mesangial IgA nephropathy is of
interest in this regard [2]. Since antibody—induced, mesangial
cell injury does alter mesangial handing of macromolecules,
direct or indirect immunologic mesangial damage in the form of
antibody and/or complement activation with inflammation could
further impair mesangial function and compound mesangial
immune—complex deposition.
Acknowledgments
This is publication No. 4250-1MM from the Department of Immunol-
ogy, Research Institute of Scripps Clinic, La Jolla, California, USA.
This work was supported in part by United States Public Health Service
Grants A107007, DK-0043, DK-32353, and AG04342; and Biomedical
Research Support Grant RRO-5514.
Reprint requests to Curtis B. Wilson, M.D., Department of Immu-
nology (IMM5), Research Institute of Scripps Clinic, 10666 North
Torrey Pines Road, La Jolla, California 92037, USA
References
1. MICHAEL AF, KEANE WF, RAU L, VERNIER RL, MAyER SM: The
glomerular mesangium. Kidney mt 17:141—154, 1980
2. LOWANCE DC, MULLINS JD, MCPHAUL JJ JR: Immunoglobulin A
(IgA) associated glomerulonephritis. Kidney mt 3:167—176, 1973
3. KEANE WF, RAU L: Impaired mesangial clearance of macromol-
ecules in rats with chronic mesangial ferritin—antiferritin immune
complex deposition. Lab Invest 43:500—508, 1980
4. MANCILLA—JIMENEZ R, BELLON B, KUHN J, BELAIR M-F,
ROUCHON M, DRUET P, BARIETY J: Phagocytosis of heat—aggre-
gated immunoglobulins by mesangial cells. An immunoperoxidase
and acid phosphatase study. Lab Invest 46:243—253, 1982
5. STERZEL RB, PABST R: The temporal relationship between glomer-
ular cell proliferation and monocyte infiltration in experimental
glomerulonephritis. Virchows Arch 38:337—350, 1982
6. Lovnrr DH, RYAN JL, STERZEL RB: A thymocyte—activating
factor derived from glomerular mesangial cells. I Immunol 130:
1796—1801, 1983
7. MACCARTHY EP, Hsu A, 0i YM, 001 BS: Evidence for a mouse
mesangial cell—derived factor that stimulates lymphocyte prolifer-
ation. J Clin Invest 76:426—430, 1985
8. STRIKER GE, STRIKER Li: Biology of disease. Glomerular cell
culture. Lab Invest 53:122—131, 1985
9. AUSIELLO DA, KREISBERO JI, ROY C, KARNOVSKY MJ: Contrac-
tion of cultured rat glomerular cells of apparent mesangial origin
after stimulation with angiotensin II and arginine vasopressin. J
Clin Invest 65:754—760, 1980
10. CATIELL V, BRADFIELD JWB: Focal mesangial proliferative gb-
merubonephritis in the rat caused by Habu snake venom. A mor-
phological study. Am J Pathol 87:511—524, 1977
11. MORITA T, KIHARA I, OITE T, YAMAMOTO T, SUZUKI Y: Mesangi-
olysis. Sequential ultrastructural study of Habu venom—induced
glomerular lesions. Lab Invest 38:94—102, 1978
12. ISHIZAKI M, SATO S, SANO J, FUKUDA Y, SUGISAKI Y, MASUGI Y:
The presence of Thy- 1.1 antigen in rat glomerular mesangial cells.
Biomed Res 1:438—442, 1980
13. BARCLAY AN: Different reticular elements in rat lymphoid tissue
identified by localization of Ia, Thy-I and MRC OX 2 antigens.
Immunology 44:727—736, 1981
14. HARADA K, YAMAMOTO T, HARA M, KIHARA I: Antigenic associ-
ation between kidney and thymocyte. Acta Pat ho! Jpn 32:483—489,
1982
15. PAUL LC, RENNKE HG, MILFORD EL, CARPENTER CB: Thy-1.1 in
glomeruli of rat kidneys. Kidney mt 25:771—777, 1984
16. YAMAMOTO T, YAMAMOTO K, KAWASAKI K, YAOITA E, SHIMIZU
F, KIHARA I: Immunoelectron microscopic demonstration of Thy-i
antigen on the surfaces of mesangial cells in the rat glomerulus.
Nephron 43:293—298, 1986
17. BAOCHUS WM, DONGA J, HOEDMAEKER PJ, BARKER WW: The
specificity of nephritogenic antibodies. 11. Immune complex gb-
merulopathy in rats induced by heterologous antithymocyte serum.
Transplantation 38: 165—169, 1984
18. YAMAMOTO T, WILSON CB: Antibody—induced mesangial cell
damage: The model, functional alterations and effect of comple-
ment. (abstract) Kidney mt 29:2%, 1986
19. BAGCHUS WM, HOEDEMAEKER PJ, R0zING J, BAKKER WW: Acute
glomerulonephritis after intravenous injection of monocbonal anti-
thymocyte antibodies in the rat. Immuno! Let 12:109—113, 1986
20. BAGCHUS WM, HOEDEMAEKER PJ, ROZING J, BAKKER WW:
Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibod-
ies. A sequential histologic and ultrastructural study in the rat. Lab
Invest 55:680—687, 1987
21. WILSON CB, DIXON FJ, FORTNER JG, CERILLI GJ: Gbomerular
basement membrane—reactive antibody in anti-lymphocyte globu-
lin. J Clin Invest 50:1525—1535, 1971
22. HOUSE PDR, PouLls P. WEIDEMANN MJ: Isolation of a plasma—
membrane subfraction from rat liver containing an insulin—sensitive
cyclic-AMP phosphodiesterase. Eur J Biochem 24:429—437, 1972
23. WILsoN CB, DIXON FJ: Antigen quantitation in experimental
immune complex glomerulonephritis. I. Acute serum sickness. J
Immunol 105:279—290, 1970
24. HEINEGARD D, TIDERSTROM G: Determination of serum creatinine
by a direct coborimetnc method. Clin Chem Acta 43:305—3 10, 1973
25. MCCONAHEY PJ, DIXON FJ: A method of trace iodination of
proteins for immunologic studies. mt Arch Allergy 29:185—189, 1966
26. ISHIZAKA K, IsrnzAKA T: Biologic activity of aggregated gam-
ma—globulin. H. A study of various methods for aggregation and
species differences. I Immunol 85:163—171, 1960
27. HEIDELBERGER M, KENDALL FE: A quantitative theory of the
precipitin reaction. Ill. The reaction between crystalline egg albu-
min and its homologous antibody. I Exp Med 62:697—720, 1935
28. CREIGHTON WD, LAMBERT PH, MIESCHER PA: Detection of anti-
bodies and soluble antigen—antibody complexes by precipitation
with polyethylene glycol. I Immunol 111:1219-1227, 1973
29. STRASSBERG J, PAULE J, GONICK HC, MAXWELL MH, KLEEMAN
CR: The quantitative estimation of perfusible gbomeruli and the
collagen and non-collagen nitrogen of the normal kidney. Nephron
4:384—393, 1967
30. WILSON CB, DIXON FJ: The renal response to immunological
injury, in The Kidney (3rd ed), edited by BRENNER BM, RECTOR,
FC JR, Philadelphia, Saunders, 1986, pp. 800—889.
31. MATSUO S, CALDWELL PRB, BRENTJENS JR. ANDRES 0: Nephro-
toxic serum glomerulonephritis induced in the rabbit by anti-
endothelial antibodies. (abstract) Kidney Int 27:2 17, 1985
32. MATSUO S, CALOWELL PRB, BRENTJENS JR, ANDRES 0: In vivo
interaction of antibodies with cell surface antigens: A mechanism
responsible for in situ formation of immune deposits in the zona
pellucida of rabbit oocytes. I Clin Invest 75:1369—1380, 1985
33. NEALE TJ, WOODROFFE AJ, WILSON CB: Spontaneous glomerubo-
nephritis in rabbits: Role of a glomerular capillary antigen. Kidney
Int 26:701—711, 1984
34. KERJASCHKI D, FARQUHAR MG: The pathogenic antigen of Hey-
mann nephritis is a membrane glycoprotein of the renal proximal
tubule brush border. Proc Nat! Acad Sci USA 79:5557—5561, 1982
35. CAMUSSI G, BRENTJENS JR, NOBLE B, KERJASCHKI D, MALAVASI
H, ROHOLT OA, FARQUHAR MG, ANDRES G: Antibody—induced
redistribution of Heymann antigen on the surface of cultured
glomerular visceral epithelial cells: Possible role in the pathogene-
sis of Heymann gbomerubonephritis. I Immunol 135:2409—2416,
1985
36. RoNco P, NEALE TJ, WILSON CB, GALCERAN M, VERROUST P: An
immunopathologic study of a 330-kD protein defined by monocbonal
antibodies and reactive with anti-RTE-alpha-5 antibodies and kid-
ney eluates from active Heymann nephritis. I Immunol 136:125—
130, 1986
37. MENDRICK DL, NOBEL B, BRENTJENS JR, ANDRES GA: Antibody—
mediated injury to proximal tubules in Heymann nephritis. Kidney
mt 18:328—343, 1980
38. NOBLE B, MENDRICK DL, BRENTJENS JR, ANDRES GA: Antibody—
mediated injury to proximal tubules in the rat kidney induced by
passive transfer of homologous anti-brush border serum. Clln
Immunol Immunopathol 19:289—301, 1981
39. IIDAKA K, MCCOY J, KIMMELSTIEL P: The gbomerular mesangium.
Antibody—induced mesangial cell damage 525
A quantitative analysis. Lab Invest 19:573—579, i%8
40. REIF AE, ALLEN JMV: The AKR thymic antigen and its distribu-
tion in leukemia and nervous tissues. J Exp Med 120:413—433, 1964
41. ACTON RT, MORRIS RI, WILLIAMS AF: Estimation of the amount
and tissue distribution of rat Thy-1.l antigen. Eur J Immunol
4:598—602, 1974
42. WILLIAMS AF: Many cells in rat bone marrow have cell—surface
Thy-i antigen. Eur J Immunol 6:526—528, 1976
43. UNANUE ER, DixoN FJ: Experimental glomerulonephritis. V.
Studies of the interaction of nephrotoxic antibodies with tissues of
the rat. JExp Med 121:697—714, 1965
44. GOLBUS SM, WILSON CB: Experimental glomerulonephritis in-
duced by in situ formation of immune complexes in glomerular
capillary wall. Kidney mt 16:148—157, 1979
45. YAMAMOTO T, WILSON CB: Mesangial cell (MC) injury and prolif-
eration produced by antibody: A role for the membrane attack
complex (MAC). (abstract) Kidney mt 31:333, 1987
46. YAMAMOTO T, WILSON CB: Complement dependence of antibody—
induced mesangial cell injury in the rat. J Immunol 138:3758—3765,
1987
47. MULLER—EBERHARD HJ: The membrane attack complex. Springer
Semin Immunopathol 7:93—141, 1984
48. STRIKER GE, MANNIK M, TUNG MY: Role of marrow derived
monocytes and mesangial cells in removal of immune complexes
from renal glomeruli. J Exp Med 149:127—136, 1979
49. SCHREINER GF, COTRAN RS: Localization of an Ia-bearing glomer-
ular cell in the mesangium. J Cell Biol 94:483—488, 1982
50. SCI-IREINER GF, UNANUE ER: Origin of the rat mesangial phago-
cyte and its expression of the leukocyte common antigen. Lab
Invest 51:515—523, 1984
